Table 2.
Univariate analysis of outcomes in patients treated with CAR-T cells.
| All Patients (n=48) | T-normal (n=22) | T-defect (n=26) | P | |
|---|---|---|---|---|
| Characteristics of patients | ||||
| HBV/HCV infection | 18 (37.5%) | 10 (45.5%) | 8 (30.8%) | 0.295 |
| Bone marrow involvement | 14 (29.8%) | 4 (18.2%) | 10 (40.0%) | 0.103 |
| P53 deletion detected by FISH | 14 (46.7%) | 7 (50.0%) | 7 (43.8%) | 0.703 |
| Double-hit/triple-hit lymphoma | 4 (21.1%) | 0 (0.0%) | 4 (21.1%) | 0.164 |
| TP53 mutation | 15 (38.5%) | 5 (26.3%) | 10 (50.0%) | 0.129 |
| Tumor maximum diameter (cm) | 4.30 (2.10-6.75) | 3.40 (1.65-4.50) | 4.90 (4.10-9.20) | 0.010 |
| Bendamustine | 2 (4.2%) | 0 (0.0%) | 2 (7.7%) | 0.189 |
| Leukapheresis related factors | ||||
| Days from initial diagnosis to leukapheresis | 456.0 (295.5-770.75) | 537.0 (327.5-827.0) | 400.0 (221.0-683.0) | 0.175 |
| LDH level before leukapheresis | 240.50 (198.5-787.3) | 222.0 (190.0-329.5) | 307.0 (210.00-559.0) | 0.020 |
| Platinum-based drugs (3 months) | 22 (45.8%) | 10 (45.5%) | 11 (42.3%) | 0.827 |
| CTX (3 months) | 15 (31.3%) | 5 (22.7%) | 10 (38.4%) | 0.241 |
| Lenalidomide (3 months) | 3 (6.3%) | 2 (9.1%) | 1 (3.8%) | 0.454 |
| CAR T-cell infusion-related factors | ||||
| Days from initial diagnosis to CAR T-cell infusion | 463.0 (298.0-787.3) | 554.0 (309.5-841.0) | 420.0 (236.0-694.0) | 0.247 |
| LDH level before CAR T-cell infusion (IU/L) | 356.0 (195.8-414.8) | 244.0 (186.0-557.5) | 472.0 (255.0-685.0) | 0.153 |
| Maximum LDH level prior to CAR T-cell infusion (IU/L) | 520.0 (274.5-1208.0) | 365.0 (243.0-1012.5) | 795.0 (414.0-1590.0) | 0.102 |
| CRS | 0.013 | |||
| Grade 0 | 14.9 (29.2%) | 2 (9.1%) | 12 (46.2%) | |
| Grade 1 | 19 (41.3%) | 9 (40.9%) | 10 (38.5%) | |
| Grade 2 | 13 (28.3%) | 9 (40.9%) | 4 (15.4%) | |
| Grade 3 | 2 (4.3%) | 2 (9.1%) | 0 (0.0%) | |
| Grade 4 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Dexamethasone | 12 (25%) | 6 (27.3%) | 6 (23.1%) | 0.738 |
Values in bold refer to P-value <0.05. CRS, cytokine release syndrome; CTX, cyclophosphamide; FISH, fluorescence in situ hybridization; HBV, hepatitis B virus; HCV, hepatitis C virus; LDH, lactate dehydrogenase.